{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:55:03Z","timestamp":1781844903593,"version":"3.54.5"},"reference-count":27,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jiangsu Provincial Hospital Association","award":["JSYGY-3-2024-YS58"],"award-info":[{"award-number":["JSYGY-3-2024-YS58"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>To investigate the predictive factors for resistance to VEN combined with HMAs in the treatment of AML, construct a drug resistance prediction model, and visualize the model. A retrospective analysis was conducted on 74 AML patients. Multivariate logistic regression was used to identify independent predictors of primary resistance, based on which a nomogram model and a risk scoring system for drug resistance were constructed. The results showed that KIT (p = 0.012), TP53 (p = 0.010), and FAB-M5 (p = 0.059) were significantly associated with primary resistance to VEN. A nomogram prediction model incorporating FAB-M5, KIT, and TP53 was established. Based on the nomogram model, a drug resistance prediction scoring tool comprising three variables was developed, categorizing patients into high-risk (6\u201310 points), intermediate-risk (3\u20135 points), and low-risk (0\u20132 points) groups. Significant differences in NR rates were observed among the three risk groups (p &lt; 0.001). KIT, TP53, and FAB-M5 are independent factors influencing VEN resistance. The constructed nomogram prediction model and scoring system may provide valuable references for predicting primary resistance to VEN.<\/jats:p>","DOI":"10.3390\/curroncol33060357","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:59:47Z","timestamp":1781503187000},"page":"357","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Nomogram Prediction Model and Scoring System for Resistance in Acute Myeloid Leukemia Patients Treated with Venetoclax Combined with Hypomethylating Agents"],"prefix":"10.3390","volume":"33","author":[{"given":"Qingqing","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-6003","authenticated-orcid":false,"given":"Yongqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"},{"name":"Research Division of Clinical Pharmacology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-Term Follow-Up of VIALE-A: Venetoclax and Azacitidine in Chemotherapy-Ineligible Untreated Acute Myeloid Leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1007\/s00277-025-06543-3","article-title":"Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: A meta-analysis of clinical trials and Real-World outcomes","volume":"104","author":"Simal","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41408-025-01396-5","article-title":"Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: A real-world, multicentric study","volume":"15","author":"Wurm","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1080\/14796694.2025.2587568","article-title":"Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population","volume":"21","author":"Roth","year":"2025","journal-title":"Future Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/10428194.2024.2411436","article-title":"HMA\/VEN treatment modifications and associated outcomes in IDH-mutant AML","volume":"66","author":"Chin","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Chatzilygeroudi, T., Karantanos, T., and Pappa, V. (2025). Unraveling Venetoclax Resistance: Navigating the Future of HMA\/Venetoclax-Refractory AML in the Molecular Era. Cancers, 17.","DOI":"10.3390\/cancers17091586"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Diamantidis, M.D. (2025). Factors affecting response and resistance to venetoclax in acute myeloid leukemia. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1577908"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"217853","DOI":"10.1016\/j.canlet.2025.217853","article-title":"Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq","volume":"628","author":"Lu","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102461","DOI":"10.1016\/j.xcrm.2025.102461","article-title":"Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning","volume":"6","author":"Jin","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-023-00374-z","article-title":"Prediction model for drug response of acute myeloid leukemia patients","volume":"7","author":"Trac","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41746-025-01978-4","article-title":"Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia","volume":"8","author":"Zhang","year":"2025","journal-title":"npj Digit. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101036","DOI":"10.1016\/j.blre.2022.101036","article-title":"Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?","volume":"59","author":"Dhakal","year":"2023","journal-title":"Blood Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2019","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.biocel.2004.04.007","article-title":"Mcl-1","volume":"37","author":"Michels","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/mc.23600","article-title":"Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients","volume":"62","author":"Zong","year":"2023","journal-title":"Mol. Carcinog."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41397-024-00359-6","article-title":"Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: A retrospective study","volume":"24","author":"Li","year":"2024","journal-title":"Pharmacogenom. J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yang, X., Mei, C., He, X., He, L., Lu, X., Tong, H., and Lou, Y. (2022). Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS\/MS Method. Molecules, 27.","DOI":"10.3390\/molecules27051607"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:36:03Z","timestamp":1781843763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060357"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060357","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}